Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7

Aug 16 2017

• By Emily Hayes

Diabetes

Related Content

Lilly's Trulicity OK'd; can it top GLP-1 market?

Sep 19 2014

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

Sep 16 2016

Semaglutide Should Transform Novo Nordisk's Prospects, CSO Says

May 31 2017

Lilly's Performance Contract For Trulicity Hinges On Head-To-Head Superiority

Jun 29 2016

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

AstraZeneca PLC

Merck & Co., Inc.

Additional Topics

Clinical Trials Market Intelligence Market Access Research & Development Metabolic Disorders BioPharmaceutical

More from Alimentary/Metabolic

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window